2. MAPK/ERK Pathway Protein Tyrosine Kinase/RTK Autophagy Apoptosis
  3. Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis
  4. Sorafenib

Sorafenib  (Synonyms: 索拉非尼; Bay 43-9006)

目录号: HY-10201 纯度: 99.92%
COA 产品使用指南

摩尔计算器

Sorafenib (Bay 43-9006) 是一种有效的口服活性 Raf 抑制剂，对 Raf-1 和 B-Raf 的 IC50 分别为 6 nM 和 20 nM。Sorafenib 是一种多激酶抑制剂，对 VEGFR2，VEGFR3，PDGFRβ，FLT3 和 c-Kit 的 IC50 分别为 90 nM，15 nM，20 nM，57 nM 和 58 nM。Sorafenib 诱导细胞自噬 (autophagy) 和凋亡 (apoptosis)，并具有抗肿瘤活性。Sorafenib 也是一种 ferroptosis 激动剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sorafenib Chemical Structure

Sorafenib Chemical Structure

CAS No. : 284461-73-0

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥500
In-stock
5 mg ￥274
In-stock
10 mg ￥411
In-stock
50 mg ￥650
In-stock
100 mg ￥850
In-stock
500 mg ￥1200
In-stock
1 g ￥1825
In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Sorafenib:

Sorafenib 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 193 篇科研文献

WB
RT-PCR
Cell Viability Assay
Proliferation Assay

    Sorafenib purchased from MCE. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83.  [Abstract]

    Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.

    Sorafenib purchased from MCE. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83.  [Abstract]

    Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.

    Sorafenib purchased from MCE. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585.  [Abstract]

    Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.

    Sorafenib purchased from MCE. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532.  [Abstract]

    SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.

    Sorafenib purchased from MCE. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983.  [Abstract]

    The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.

    Sorafenib purchased from MCE. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514.  [Abstract]

    VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.

    Sorafenib purchased from MCE. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229.  [Abstract]

    The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.

    Sorafenib purchased from MCE. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123.  [Abstract]

    Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W

    Sorafenib purchased from MCE. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123.  [Abstract]

    Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

    Sorafenib purchased from MCE. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784.  [Abstract]

    Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.

    Sorafenib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.  [Abstract]

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

    Sorafenib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.  [Abstract]

    The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

    查看 Raf 亚型特异性产品:

    查看所有亚型
    BRaf c-Raf Raf

    查看 VEGFR 亚型特异性产品:

    查看所有亚型
    VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

    IC50 & Target[1]

    VEGFR3

    20 nM (IC50)

    Braf

    22 nM (IC50)

    Raf-1

    6 nM (IC50)

    VEGFR2

    90 nM (IC50)

    PDGFRβ

    57 nM (IC50)

    BrafV599E

    38 nM (IC50)

    c-Kit

    68 nM (IC50)

    Flt3

    58 nM (IC50)

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    786-0 IC50
    13 μM
    Compound: Sora
    Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    786-0 IC50
    15.62 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    786-0 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    786-0 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    786-0 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB method
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    786-0 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    786-0 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    786-0 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    786-0 IC50
    4.9 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay
    		[PMID: 29517908]
    786-0 IC50
    4.9 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    		[PMID: 29297688]
    786-0 IC50
    5.3 μM
    Compound: Sorafenib
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
    		[PMID: 29786436]
    8505C IC50
    4.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay
    Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    A2058 IC50
    3.8 μM
    Compound: sorafenib
    Cytotoxicity against human A2058 cells after 48 hrs by MTT assay
    Cytotoxicity against human A2058 cells after 48 hrs by MTT assay
    		[PMID: 22708987]
    A-375 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    A-375 IC50
    10.28 μM
    Compound: Sorafenib
    Cytotoxicity against human A-375 cells by MTT assay
    Cytotoxicity against human A-375 cells by MTT assay
    		[PMID: 33316752]
    A-375 IC50
    13.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    A-375 IC50
    13.64 μM
    Compound: 3
    Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay
    		[PMID: 25462267]
    A-375 IC50
    13.64 μM
    Compound: Sorafenib
    Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    A-375 IC50
    16.24 μM
    Compound: Sorafenib
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25461318]
    A-375 IC50
    2200 nM
    Compound: Sorafenib
    Toxicity against human A375 cells after 72 hrs by cell titer-blue assay
    Toxicity against human A375 cells after 72 hrs by cell titer-blue assay
    		[PMID: 19654408]
    A-375 IC50
    3.36 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    		[PMID: 29602674]
    A-375 IC50
    5.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    		[PMID: 20056548]
    A-375 IC50
    5.4 μM
    Compound: sorafenib
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
    		[PMID: 18477505]
    A-375 IC50
    5.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells by MTT assay
    Antiproliferative activity against human A375 cells by MTT assay
    		[PMID: 19464887]
    A-375 IC50
    5.6 μM
    Compound: Sorafenib, Nexavar
    Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum
    Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum
    		[PMID: 21592628]
    A-375 IC50
    7.56 μM
    Compound: Sorafenib
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    		[PMID: 24215818]
    A-375 IC50
    7.88 μM
    Compound: Sorafenib
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30955995]
    A-375 IC50
    8.33 μM
    Compound: Sorafenib
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    		[PMID: 29886324]
    A-375 IC50
    9.17 μM
    Compound: Sorafenib
    Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    A-431 IC50
    10.46 μM
    Compound: Sorafenib
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    A-431 IC50
    3.32 μM
    Compound: Sorafenib
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    A498 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    A498 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    A498 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human A498 cells after 48 hrs by SRB method
    Cytotoxicity against human A498 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    A498 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    A498 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    A498 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    A549 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    A549 IC50
    0.63 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25982075]
    A549 IC50
    0.75 μM
    Compound: Sorafenib
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    A549 IC50
    1.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 33129590]
    A549 IC50
    1.45 μM
    Compound: BAY-43-9006
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    		[PMID: 26342134]
    A549 IC50
    1.92 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    A549 IC50
    10.7 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    A549 IC50
    11.24 mM
    Compound: Sorafenib
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    A549 IC50
    12.54 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    A549 IC50
    13.64 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 26560049]
    A549 IC50
    180 nM
    Compound: Sorafenib
    Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method
    Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method
    		[PMID: 30826508]
    A549 IC50
    19.3 μM
    Compound: Sorafenib
    Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay
    		[PMID: 30108994]
    A549 IC50
    19.54 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    A549 IC50
    2.02 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26753815]
    A549 IC50
    2.9 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    A549 IC50
    2.92 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    A549 IC50
    2.92 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    A549 IC50
    25.671 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    A549 IC50
    27 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    A549 IC50
    27 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    		[PMID: 30502686]
    A549 IC50
    27.71 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    A549 IC50
    3.1 μM
    Compound: Sorafenib
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    A549 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    A549 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    A549 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    A549 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    A549 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    A549 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    A549 IC50
    3.19 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    A549 IC50
    3.36 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    A549 IC50
    3.779 μg/mL
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay
    		[PMID: 29395969]
    A549 IC50
    3.88 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    A549 IC50
    4 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    A549 GI50
    4.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    A549 IC50
    4.47 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    A549 IC50
    4.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 23260578]
    A549 IC50
    5 μM
    Compound: 1
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34634618]
    A549 IC50
    5.13 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    A549 IC50
    5.21 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    		[PMID: 20181414]
    A549 IC50
    5.231 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		10.1039/C2MD20275A
    A549 IC50
    5.53 μM
    Compound: Sorafenib
    Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method
    Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method
    		[PMID: 30826508]
    A549 IC50
    5.62 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 32663641]
    A549 IC50
    6.08 μM
    Compound: Sorafenib
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0398-y
    A549 IC50
    6.11 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    A549 IC50
    6.21 μM
    Compound: Sorafenib
    Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    A549 IC50
    6.53 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28340913]
    A549 IC50
    6.53 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27043268]
    A549 IC50
    6.7 μM
    Compound: Sorafenib
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    A549 IC50
    6.83 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    A549 IC50
    64.9 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    A549 IC50
    7.43 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    A549 IC50
    7.62 μM
    Compound: C1
    Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    A549 IC50
    8.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    ACHN IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    ACHN GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    ACHN IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    ACHN GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    ACHN GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    ACHN GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human ACHN cells after 48 hrs by SRB method
    Cytotoxicity against human ACHN cells after 48 hrs by SRB method
    		[PMID: 26590508]
    ACHN IC50
    3.3 μM
    Compound: Sora
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    ACHN IC50
    3.4 μM
    Compound: Sorafenib
    Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay
    		[PMID: 29517908]
    ACHN IC50
    3.4 μM
    Compound: Sorafenib
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    		[PMID: 29297688]
    ACHN IC50
    3.5 μM
    Compound: Sorafenib
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
    		[PMID: 29786436]
    B16-BL6 IC50
    36.48 μM
    Compound: Sorafenib
    Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay
    		[PMID: 29631788]
    B16-F1 IC50
    4.9 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    		[PMID: 20056548]
    B16-F1 IC50
    4.9 μM
    Compound: sorafenib
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
    		[PMID: 18477505]
    BaF3 IC50
    > 10 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    0.006 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 IC50
    0.012 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    0.013 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    0.014 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    0.078 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 GI50
    0.23 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 IC50
    1.015 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 GI50
    1.1 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 IC50
    1.112 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 GI50
    1.28 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 IC50
    1.348 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 IC50
    1.454 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BaF3 GI50
    1.8 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 GI50
    1542 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 IC50
    2.458 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 GI50
    2.8 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 IC50
    2.804 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 GI50
    206.2 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    2637 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 IC50
    3.681 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    4.208 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    5.82 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 GI50
    5417 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    56.5 nM
    Compound: Sorafenib
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
    		[PMID: 34324343]
    BaF3 GI50
    6.36 μM
    Compound: Sorafenib
    Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
    		[PMID: 29133048]
    BaF3 IC50
    7.4 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
    		[PMID: 26629594]
    BaF3 IC50
    7.997 μM
    Compound: Sorafenib
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    BCPAP IC50
    6.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay
    Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    Bel-7402 IC50
    10.26 μM
    Compound: sorafenib
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    Bel-7402 IC50
    10.31 μM
    Compound: Sorafenib
    Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay
    Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    Bel-7402 IC50
    10.87 μM
    Compound: Cpd S
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32827851]
    Bel-7402 IC50
    4.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    Bel-7402 IC50
    5.8 μM
    Compound: Sorafenib
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    Bel-7402 IC50
    6.03 μM
    Compound: Sorafenib
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    Bel7402/5-FU IC50
    13.31 μM
    Compound: Sorafenib
    Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    BEL-7404 tumor cell line IC50
    92 μM
    Compound: Sorafenib
    Antiproliferative activity against human BEL-7404 tumor cell line assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human BEL-7404 tumor cell line assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 30114660]
    BGC-823 IC50
    10.91 μM
    Compound: Sorafenib
    Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 22721924]
    BGC-823 IC50
    3 μM
    Compound: Sorafenib
    Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    BT-549 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    BT-549 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    BT-549 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human BT549 cells after 48 hrs by SRB method
    Cytotoxicity against human BT549 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    BT-549 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    BT-549 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    BT-549 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    BXPC-3 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    C6 IC50
    8.17 μM
    Compound: Sorafenib
    Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    CAKI-1 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    CAKI-1 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    CAKI-1 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB method
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    CAKI-1 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    CAKI-1 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    CAKI-1 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    CAKI-2 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    CCRF-CEM IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    CCRF-CEM GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    CCRF-CEM GI50
    2 μM
    Compound: 1
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method
    		[PMID: 26590508]
    CCRF-CEM IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    CCRF-CEM GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    CCRF-CEM GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    COLO 205 IC50
    > 3 μM
    Compound: Sorafenib
    Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    COLO 205 IC50
    0.87 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    COLO 205 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    COLO 205 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    COLO 205 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB method
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    COLO 205 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    COLO 205 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    COLO 205 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    COLO 205 IC50
    7.04 μM
    Compound: Sorafenib
    Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    CT26 GI50
    14.7 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    CT26 IC50
    2.1 μM
    Compound: Sorafenib
    Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    CT26 GI50
    30.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    DU-145 IC50
    24.91 μM
    Compound: Sorafenib
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    DU-145 IC50
    24.91 μM
    Compound: Sorafenib
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    DU-145 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    DU-145 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    DU-145 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    DU-145 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    DU-145 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    DU-145 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    DU-145 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    DU-145 IC50
    5.1 μM
    Compound: sorafenib
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 22708987]
    DU-145 IC50
    83.736 μM
    Compound: Sorafenib
    Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    EA.hy 926 IC50
    11.02 μM
    Compound: Sorafenib
    Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36508995]
    EA.hy 926 IC50
    11.74 μM
    Compound: Sorafenib
    Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 30616052]
    EA.hy 926 IC50
    11.74 μM
    Compound: Sorafenib
    Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay
    Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay
    		[PMID: 30503935]
    EA.hy 926 IC50
    18.52 μM
    Compound: Sorafenib
    Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay
    Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay
    		[PMID: 29032031]
    EA.hy 926 IC50
    24.36 μM
    Compound: Sorafenib
    Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay
    Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay
    		[PMID: 29102175]
    EA.hy 926 IC50
    24.36 μM
    Compound: Sorafenib
    Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay
    Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay
    		[PMID: 28068599]
    EJ IC50
    22.9 μM
    Compound: Sorafenib
    Cytotoxicity against human EJ cells after 48 hrs by MTT assay
    Cytotoxicity against human EJ cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    EKVX IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    EKVX GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    EKVX GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    EKVX GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    EOL1 IC50
    2.3 nM
    Compound: 4
    Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay
    Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay
    		10.1039/C1MD00175B
    Fibroblast IC50
    15.1 μM
    Compound: Sorafenib
    Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
    Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
    		[PMID: 20056548]
    Fibroblast IC50
    15.1 μM
    Compound: sorafenib
    Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay
    Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay
    		[PMID: 18477505]
    Fibroblast IC50
    15.1 μM
    Compound: sorafenib, velcade
    Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay
    Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay
    		[PMID: 17561392]
    GES1 IC50
    10.68 μM
    Compound: Sorafenib
    Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27162123]
    GES1 IC50
    15.8 μM
    Compound: Sorafenib
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    		[PMID: 23871909]
    GES1 GI50
    15.9 μM
    Compound: Sorafenib
    Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    GES1 GI50
    28.9 μM
    Compound: Sorafenib
    Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    GES1 IC50
    9.47 μM
    Compound: Sorafenib
    Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    GES1 IC50
    9.59 μM
    Compound: Sorafenib
    Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33493829]
    HCC 2998 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HCC 2998 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HCC 2998 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    HCC 2998 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HCC 2998 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HCC 2998 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HCCLM9 IC50
    21.07 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HCCLM9 IC50
    3.15 μM
    Compound: sorafenib
    Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    HCT-116 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HCT-116 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HCT-116 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB method
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HCT-116 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HCT-116 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HCT-116 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HCT-116 IC50
    16.12 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HCT-116 IC50
    168 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    HCT-116 GI50
    19.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    HCT-116 IC50
    2.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 23260578]
    HCT-116 IC50
    23.31 μM
    Compound: Sorafenib
    Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 29602674]
    HCT-116 GI50
    5.4 μM
    Compound: BAY-439006
    Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay
    Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay
    		[PMID: 15225706]
    HCT-116 GI50
    5.42 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34147745]
    HCT-116 IC50
    5.47 μM
    Compound: SOR
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HCT-116 IC50
    5.65 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 24215818]
    HCT-116 IC50
    7.75 μM
    Compound: Sorafenib
    Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0400-8
    HCT-116 IC50
    7.8 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 22483592]
    HCT-116 IC50
    8.08 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 24440479]
    HCT-116 IC50
    8.08 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    HCT-116 IC50
    8.41 μM
    Compound: Sorafenib
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 29631788]
    HCT-116 IC50
    8.41 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT116 cells by MTT assay
    Antiproliferative activity against human HCT116 cells by MTT assay
    		10.1039/C4MD00536H
    HCT-116 GI50
    9 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    HCT-116 IC50
    9.4 μM
    Compound: 1; BAY-43-9006
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    HCT-15 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HCT-15 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB method
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HCT-15 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HCT-15 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HEK293 IC50
    0.12 μM
    Compound: Sorafenib
    Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP
    Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP
    		[PMID: 26318998]
    HEK293 IC50
    2.95 μM
    Compound: Sorafenib
    Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    		[PMID: 35635929]
    HEK293 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay
    Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HEK293 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against HEK293 cells by MTT assay
    Antiproliferative activity against HEK293 cells by MTT assay
    		[PMID: 30502686]
    HEK-293T IC50
    6.38 μM
    Compound: Sorafenib
    Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    HeLa IC50
    12.01 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29103873]
    HeLa IC50
    2.44 μM
    Compound: Sorafenib
    Growth inhibition of human HeLa cells after 48 hrs by MTT assay
    Growth inhibition of human HeLa cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    HeLa IC50
    3.31 μM
    Compound: SFN
    Cytotoxicity against human HeLa cells by SRB assay
    Cytotoxicity against human HeLa cells by SRB assay
    		[PMID: 36067930]
    HeLa IC50
    4.163 μM
    Compound: Sorafenib
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23362959]
    HeLa IC50
    4.59 μM
    Compound: Sorafenib
    Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
    		[PMID: 30108964]
    HeLa IC50
    5.23 μM
    Compound: Sorafenib
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26342867]
    HeLa IC50
    6.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HeLa IC50
    6.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    		[PMID: 30502686]
    HeLa IC50
    7.68 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    HeLa IC50
    8.04 μM
    Compound: SOR
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HeLa IC50
    8.74 μM
    Compound: Sorafenib
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    Hep 3B2 IC50
    11.2 μM
    Compound: Sorafenib
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    		[PMID: 28342400]
    Hep 3B2 IC50
    12.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    		[PMID: 36461923]
    Hep 3B2 IC50
    14.08 μM
    Compound: sorafenib
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    Hep 3B2 IC50
    2.63 μM
    Compound: Sorafenib
    Growth inhibition of human Hep3B cells after 48 hrs by MTT assay
    Growth inhibition of human Hep3B cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    Hep 3B2 IC50
    4.01 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells measured by MTT assay
    Antiproliferative activity against human Hep3B cells measured by MTT assay
    		[PMID: 35764033]
    Hep 3B2 IC50
    4.33 μM
    Compound: Sor
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    Hep 3B2 IC50
    5.2 μM
    Compound: Sorafenib
    Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36223633]
    Hep 3B2 IC50
    5.2 μM
    Compound: Sorafenib
    Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay
    Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32371334]
    Hep 3B2 IC50
    5.49 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    Hep 3B2 IC50
    7.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36745506]
    Hep 3B2 IC50
    8.62 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    Hep 3B2 IC50
    9.4 μM
    Compound: Sorafenib
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    Hepatocyte IC50
    16.55 μM
    Compound: Sorafenib
    Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay
    Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay
    		[PMID: 34479065]
    HepG2 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    HepG2 IC50
    1.06 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 29628325]
    HepG2 IC50
    10.48 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		10.1039/C4MD00536H
    HepG2 IC50
    11.49 μM
    Compound: sorafenib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    HepG2 IC50
    12 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    		[PMID: 27422336]
    HepG2 IC50
    12.4 μg/mL
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 29103873]
    HepG2 IC50
    12.54 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    HepG2 IC50
    12.669 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		10.1039/C2MD20275A
    HepG2 IC50
    15 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29103873]
    HepG2 IC50
    16.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay
    		[PMID: 30114660]
    HepG2 IC50
    16.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    		[PMID: 36461923]
    HepG2 IC50
    2.1 μM
    Compound: sorafenib
    Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    HepG2 IC50
    2.17 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    		[PMID: 34479065]
    HepG2 IC50
    2.41 μM
    Compound: C1
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    HepG2 GI50
    2.5 μM
    Compound: 3
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay
    		[PMID: 32272419]
    HepG2 IC50
    2.69 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36508995]
    HepG2 IC50
    2.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    HepG2 IC50
    2.84 μM
    Compound: Sorafenib
    Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    HepG2 IC50
    2.86 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells measured by MTT assay
    Antiproliferative activity against human HepG2 cells measured by MTT assay
    		[PMID: 35764033]
    HepG2 IC50
    29 μM
    Compound: Sorafenib
    Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay
    		[PMID: 30108994]
    HepG2 IC50
    29.35 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HepG2 IC50
    29.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    HepG2 IC50
    3.04 μM
    Compound: 1
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    HepG2 IC50
    3.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    HepG2 IC50
    3.4 μM
    Compound: Sorafenib
    Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
    Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
    		[PMID: 26071861]
    HepG2 IC50
    3.44 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    HepG2 IC50
    3.44 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    HepG2 IC50
    3.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
    		[PMID: 25462265]
    HepG2 IC50
    3.5 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells by sulforhodamine B assay
    		[PMID: 31401008]
    HepG2 IC50
    3.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    HepG2 IC50
    3.66 μM
    Compound: Sor
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    HepG2 EC50
    302 nM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    HepG2 IC50
    4 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    HepG2 GI50
    4.5 μM
    Compound: BAY 43-9006, Nexavar
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 23726028]
    HepG2 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23932071]
    HepG2 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 23260578]
    HepG2 IC50
    5.06 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    HepG2 IC50
    5.06 μM
    Compound: 1
    Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36270111]
    HepG2 IC50
    5.2 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31926469]
    HepG2 IC50
    5.23 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    HepG2 IC50
    5.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36745506]
    HepG2 IC50
    5.5 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 32323991]
    HepG2 IC50
    5.74 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25461318]
    HepG2 IC50
    5.78 μM
    Compound: Sorafenib
    Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    HepG2 IC50
    6.18 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    HepG2 IC50
    6.2 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    HepG2 IC50
    6.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 23932071]
    HepG2 IC50
    6.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		[PMID: 34128674]
    HepG2 IC50
    6.5 μM
    Compound: 1
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay
    		[PMID: 33460739]
    HepG2 IC50
    6.54 μM
    Compound: SFN
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    		[PMID: 36067930]
    HepG2 IC50
    6.7 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    HepG2 IC50
    7.22 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    HepG2 IC50
    7.31 μM
    Compound: 1; BAY-43-9006
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    HepG2 IC50
    7.67 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 32791397]
    HepG2 IC50
    7.839 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    HepG2 IC50
    8 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32842729]
    HepG2 IC50
    8.42 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    HepG2 IC50
    8.42 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    HepG2 IC50
    8.67 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    HepG2 IC50
    9.14 μM
    Compound: Sorafenib
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    		[PMID: 26560049]
    HepG2 IC50
    9.18 μM
    Compound: SOR
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    HepG2 IC50
    9.64 mM
    Compound: Sorafenib
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    HepG2 IC50
    9.7 μM
    Compound: Sorafenib
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 36223633]
    HepG2 IC50
    9.75 μM
    Compound: Sorafenib
    Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32371334]
    HGC-27 IC50
    > 150 μM
    Compound: Sorafenib
    Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HGC-27 IC50
    5.15 μM
    Compound: Sorafenib
    Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    HGC-27 IC50
    5.22 μM
    Compound: Sorafenib
    Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    HK-2 IC50
    2.6 μM
    Compound: Sora
    Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    HL-60 IC50
    0.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay
    		[PMID: 35148084]
    HL-60 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HL-60 IC50
    1.68 μM
    Compound: Nexavar, Sorafenib
    Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay
    		[PMID: 24858546]
    HL-60 IC50
    2.59 μM
    Compound: Sorafenib
    Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
    		[PMID: 30108964]
    HL-60 IC50
    2.81 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HL-60 IC50
    3.14 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HL-60 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL60 cells by MTT assay
    Antiproliferative activity against human HL60 cells by MTT assay
    		[PMID: 30502686]
    HL-60(TB) IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HL-60(TB) IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    HL-60(TB) GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method
    Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HL-60(TB) IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HL-60(TB) GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HL-60(TB) GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HMEC-1 IC50
    34 μM
    Compound: Sorafenib
    Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay
    Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HMEC-1 IC50
    34 μM
    Compound: Sorafenib
    Antiproliferative activity against HMEC1 cells by MTT assay
    Antiproliferative activity against HMEC1 cells by MTT assay
    		[PMID: 30502686]
    HMEC-1 IC50
    34 μM
    Compound: Sorafenib
    Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay
    Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay
    		[PMID: 30502686]
    HOP-62 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HOP-62 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HOP-62 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB method
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HOP-62 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HOP-62 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HOP-62 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HOP-92 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HOP-92 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HOP-92 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HOP-92 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HOP-92 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HS27 GI50
    > 30 μM
    Compound: Sorafenib
    Cytotoxicity against human HS27 cells after 24 hrs by MTT assay
    Cytotoxicity against human HS27 cells after 24 hrs by MTT assay
    		[PMID: 26318067]
    HS27 IC50
    7.8 μM
    Compound: sorafenib
    Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay
    		[PMID: 19857963]
    HS27 IC50
    7.8 μM
    Compound: Sorafenib
    Cytotoxicity against human HS27 cells by MTT assay
    Cytotoxicity against human HS27 cells by MTT assay
    		[PMID: 19897366]
    HS27 GI50
    7.85 μM
    Compound: Sorafenib
    Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay
    Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 21353571]
    Hs-578T IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    Hs-578T GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    Hs-578T GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB method
    Cytotoxicity against human Hs578T cells after 48 hrs by SRB method
    		[PMID: 26590508]
    Hs-578T IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    Hs-578T GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    Hs-578T GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HT-29 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    HT-29 IC50
    > 150 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    HT-29 IC50
    0.39 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    HT-29 IC50
    10 μM
    Compound: Sorafenib
    Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    HT-29 IC50
    10.05 mM
    Compound: Sorafenib
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    HT-29 IC50
    11.51 μM
    Compound: 14
    Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis
    Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis
    		[PMID: 36346971]
    HT-29 IC50
    15.2 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    HT-29 IC50
    17 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    HT-29 IC50
    17 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells by MTT assay
    Antiproliferative activity against human HT-29 cells by MTT assay
    		[PMID: 30502686]
    HT-29 IC50
    17.28 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 32663641]
    HT-29 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    HT-29 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    HT-29 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB method
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    HT-29 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    HT-29 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    HT-29 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    HT-29 IC50
    2.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HT-29 IC50
    2.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
    		[PMID: 29886324]
    HT-29 GI50
    25.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    HT-29 GI50
    25.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    HT-29 IC50
    3.27 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    HT-29 IC50
    3.37 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    HT-29 IC50
    3.61 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    HT-29 IC50
    3.61 μM
    Compound: 5
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    HT-29 IC50
    3.61 μM
    Compound: 5
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    HT-29 IC50
    3.97 μM
    Compound: Sorafenib
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    HT-29 IC50
    4 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    HT-29 IC50
    5.29 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    HT-29 IC50
    5.57 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    		[PMID: 33493829]
    HT-29 IC50
    5.9 μM
    Compound: Sorafenib
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 28865276]
    HT-29 IC50
    6.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    HT-29 IC50
    8.44 μM
    Compound: Sorafenib
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
    		[PMID: 29602674]
    Huh-7 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    Huh-7 IC50
    10.1 μM
    Compound: Sorafenib
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32842729]
    Huh-7 IC50
    10.94 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    Huh-7 IC50
    11.3 μM
    Compound: Sorafenib
    Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay
    		[PMID: 27422336]
    Huh-7 IC50
    2.6 μM
    Compound: sorafenib
    Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    Huh-7 IC50
    2.68 μM
    Compound: Sor
    Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    Huh-7 GI50
    4 μM
    Compound: BAY 43-9006, Nexavar
    Cytotoxicity against human HuH7 cells by MTT assay
    Cytotoxicity against human HuH7 cells by MTT assay
    		[PMID: 23726028]
    Huh-7 IC50
    4.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells by MTT assay
    Antiproliferative activity against human Huh-7 cells by MTT assay
    		[PMID: 34128674]
    Huh-7 IC50
    7.1 μM
    Compound: Sorafenib
    Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    Huh-7 IC50
    7.55 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    Huh-7 IC50
    7.92 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 32791397]
    Huh-7 IC50
    9.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
    		[PMID: 36461923]
    HUVEC IC50
    0.59 nM
    Compound: sorafenib
    Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy
    Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy
    		[PMID: 18849971]
    HUVEC IC50
    1.49 μM
    Compound: Sorafenib
    Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay
    Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay
    		[PMID: 29189002]
    HUVEC IC50
    2.69 μM
    Compound: Sorafenib
    Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay
    Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay
    		[PMID: 29886324]
    HUVEC IC50
    2.8 μM
    Compound: Sorafenib
    Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay
    Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    HUVEC IC50
    4 μM
    Compound: sorafenib
    Cytotoxicity against HUVEC by MTT assay
    Cytotoxicity against HUVEC by MTT assay
    		[PMID: 23562241]
    HUVEC IC50
    4.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    HUVEC IC50
    40.6 μM
    Compound: Sorafenib
    Cytotoxicity against HUVEC after 48 hrs by MTT assay
    Cytotoxicity against HUVEC after 48 hrs by MTT assay
    		[PMID: 28342400]
    HUVEC IC50
    5.35 μM
    Compound: C1
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    HUVEC GI50
    6 μM
    Compound: BAY 43-9006, Nexavar
    Antiproliferative activity against HUVEC after 72 hrs by MTT assay
    Antiproliferative activity against HUVEC after 72 hrs by MTT assay
    		[PMID: 23726028]
    HUVEC IC50
    6.42 μM
    Compound: Sorafenib
    Antiproliferative activity against HUVEC after 48 hrs by MTT assay
    Antiproliferative activity against HUVEC after 48 hrs by MTT assay
    		[PMID: 24440479]
    HUVEC IC50
    6.42 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay
    Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    HUVEC EC50
    718 nM
    Compound: Sorafenib
    Antiangiogenic activity in HUVEC after 72 hrs by MTT assay
    Antiangiogenic activity in HUVEC after 72 hrs by MTT assay
    		[PMID: 27010810]
    HUVEC IC50
    8.33 μM
    Compound: Sorafenib
    Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 33493829]
    HUVEC IC50
    9.66 μM
    Compound: Sorafenib
    Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 36242985]
    IGROV-1 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    IGROV-1 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    IGROV-1 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method
    Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    IGROV-1 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    IGROV-1 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    IGROV-1 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    Jurkat IC50
    14.37 μM
    Compound: 14
    Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis
    Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis
    		[PMID: 36346971]
    K562 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    K562 GI50
    0.612 μM
    Compound: 3
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay
    		[PMID: 32272419]
    K562 IC50
    0.86 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    K562 IC50
    0.86 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    K562 IC50
    1.22 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    K562 IC50
    13.85 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    K562 IC50
    17.23 μM
    Compound: 1
    Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    K562 IC50
    2.81 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    K562 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    K562 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human K562 cells after 48 hrs by SRB method
    Cytotoxicity against human K562 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    K562 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    K562 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    K562 IC50
    5.08 μM
    Compound: Sor
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    K562 GI50
    6.2 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method
    Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method
    		[PMID: 21708468]
    K562 GI50
    7.3 μM
    Compound: 2
    Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    K562 GI50
    7.3 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay
    Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay
    		[PMID: 23618709]
    Kasumi 1 IC50
    0.015 μM
    Compound: 2
    Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    KB GI50
    5.43 μM
    Compound: Sorafenib
    Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    KETR3 IC50
    18.8 μM
    Compound: Sorafenib
    Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    KM12 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    KM12 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    KM12 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human KM12 cells after 48 hrs by SRB method
    Cytotoxicity against human KM12 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    KM12 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    KM12 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    KM12 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    L02 IC50
    5.98 μM
    Compound: sorafenib
    Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    L02 IC50
    52.87 μM
    Compound: Sorafenib
    Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    L02 IC50
    9.1 μM
    Compound: Sorafenib
    Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
    		[PMID: 32323991]
    LC-2-ad GI50
    3224.13 nM
    Compound: Sorafenib
    Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay
    Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay
    		[PMID: 35081714]
    LoVo IC50
    14.57 μM
    Compound: Sorafenib
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 33423463]
    LoVo IC50
    2.52 μM
    Compound: Sorafenib
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    LoVo IC50
    3.3 μM
    Compound: Sorafenib
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    LoVo IC50
    6.56 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    LoVo IC50
    6.56 μM
    Compound: Sorafenib
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    LoVo IC50
    9.47 μM
    Compound: Sorafenib
    Growth inhibition of human LoVo cells after 48 hrs by MTT assay
    Growth inhibition of human LoVo cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    LOX IMVI GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    LOX IMVI GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method
    Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method
    		[PMID: 26590508]
    LOX IMVI GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    LOX IMVI GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    LOX IMVI IC50
    4.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    M14 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    M14 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    M14 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human M14 cells after 48 hrs by SRB method
    Cytotoxicity against human M14 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    M14 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    M14 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    M14 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    Mahlavu IC50
    13.4 μM
    Compound: Sorafenib
    Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay
    Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay
    		[PMID: 36018000]
    Malme-3M IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    Malme-3M GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    Malme-3M IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    Malme-3M GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    Malme-3M GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MCF7 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    MCF7 IC50
    0.19 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25496804]
    MCF7 IC50
    0.78 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    MCF7 IC50
    1.88 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25637123]
    MCF7 IC50
    10.87 mM
    Compound: Sorafenib
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    MCF7 IC50
    11.34 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    MCF7 IC50
    11.34 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    MCF7 IC50
    14 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
    		[PMID: 30878834]
    MCF7 IC50
    14 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells by MTT assay
    Antiproliferative activity against human MCF7 cells by MTT assay
    		[PMID: 30502686]
    MCF7 IC50
    15 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay
    		[PMID: 33460739]
    MCF7 IC50
    2.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    MCF7 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MCF7 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MCF7 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MCF7 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MCF7 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MCF7 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MCF7 IC50
    2.78 μM
    Compound: Sorafenib
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    MCF7 IC50
    3.07 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
    		[PMID: 30108964]
    MCF7 IC50
    3.18 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    MCF7 IC50
    3.18 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    MCF7 IC50
    3.47 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 30616052]
    MCF7 IC50
    3.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
    		[PMID: 34479065]
    MCF7 IC50
    3.64 μM
    Compound: Sorafenib
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 29549841]
    MCF7 IC50
    38.168 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    MCF7 IC50
    4.21 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28340913]
    MCF7 IC50
    4.21 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27043268]
    MCF7 IC50
    4.27 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 30503942]
    MCF7 IC50
    4.33 μg/mL
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 28505536]
    MCF7 IC50
    4.33 μM
    Compound: I; BAY 43-9006
    Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay
    		[PMID: 31284081]
    MCF7 GI50
    4.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    MCF7 IC50
    43.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31546197]
    MCF7 IC50
    5.5 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    MCF7 IC50
    5.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    		[PMID: 36324492]
    MCF7 IC50
    7.21 μM
    Compound: 1; BAY-43-9006
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33214036]
    MCF7 IC50
    7.26 μM
    Compound: SOR
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    MCF7 IC50
    7.33 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    MCF7 IC50
    8.83 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    MCF7 IC50
    9.12 μM
    Compound: Sorafenib
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    MDA-MB-231 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27010810]
    MDA-MB-231 IC50
    0.94 μM
    Compound: 5
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    MDA-MB-231 IC50
    0.94 μM
    Compound: 5
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    MDA-MB-231 IC50
    1.26 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MDA-MB-231 GI50
    1.26 μM
    Compound: Sorafenib
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MDA-MB-231 GI50
    1.26 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MDA-MB-231 IC50
    1.26 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MDA-MB-231 GI50
    1.26 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MDA-MB-231 GI50
    1.26 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MDA-MB-231 IC50
    11.84 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    MDA-MB-231 IC50
    14.62 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 24440479]
    MDA-MB-231 IC50
    14.62 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    MDA-MB-231 IC50
    15.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31668972]
    MDA-MB-231 IC50
    17.38 μM
    Compound: C1
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
    		[PMID: 31252306]
    MDA-MB-231 IC50
    17.84 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    		10.1039/C4MD00536H
    MDA-MB-231 IC50
    2 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    MDA-MB-231 IC50
    2.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 29202403]
    MDA-MB-231 IC50
    3.08 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    MDA-MB-231 IC50
    3.81 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    MDA-MB-231 IC50
    35 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    MDA-MB-231 IC50
    35 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    MDA-MB-231 IC50
    36 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 22483592]
    MDA-MB-231 IC50
    36.6 μM
    Compound: Sorafenib
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0400-8
    MDA-MB-231 GI50
    4.13 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    		[PMID: 34147745]
    MDA-MB-231 IC50
    4.77 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    MDA-MB-231 IC50
    5.1 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    MDA-MB-231 IC50
    7.18 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 22721924]
    MDA-MB-231 IC50
    7.62 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
    		[PMID: 20181414]
    MDA-MB-231 IC50
    8.52 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    		[PMID: 34536673]
    MDA-MB-435 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MDA-MB-435 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MDA-MB-435 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MDA-MB-435 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MDA-MB-435 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MDA-MB-435 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MDA-MB-435 IC50
    1.67 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    MDA-MB-435 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    MDA-MB-435 IC50
    2.11 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay
    Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 29189002]
    MDA-MB-436 IC50
    4.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 29202403]
    MDA-MB-468 IC50
    12.17 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    MDA-MB-468 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    MDA-MB-468 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MDA-MB-468 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MDA-MB-468 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MDA-MB-468 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MDA-MB-468 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MDA-MB-468 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MDA-MB-468 IC50
    4.9 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 26159483]
    MDA-MB-468 IC50
    7.31 μM
    Compound: Sorafenib
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
    		[PMID: 35635929]
    MGC-803 IC50
    19.92 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 29103873]
    MGC-803 IC50
    50.78 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    MGC-803 IC50
    7.99 μM
    Compound: Cpd S
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 32827851]
    MGC-803 IC50
    7.99 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC803 cells by MTT assay
    Antiproliferative activity against human MGC803 cells by MTT assay
    		[PMID: 26560049]
    MGC-803 IC50
    9.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    MHCC97H IC50
    9.32 μM
    Compound: Sorafenib
    Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay
    Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    MIA PaCa-2 IC50
    9.32 μM
    Compound: Sorafenib
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    MKN-28 IC50
    17 μM
    Compound: Sorafenib
    Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    MKN-45 IC50
    2.32 μM
    Compound: Sorafenib
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    MKN-45 IC50
    2.32 μM
    Compound: 5
    Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    MKN-45 IC50
    2.32 μM
    Compound: 5
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    MOLM-13 IC50
    > 3 μM
    Compound: Sorafenib
    Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs
    Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs
    		[PMID: 24641103]
    MOLM-13 IC50
    > 3 μM
    Compound: Sorafenib
    Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    MOLM-13 IC50
    0.002 μM
    Compound: Sorafenib
    Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs
    Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs
    		[PMID: 24641103]
    MOLM-13 IC50
    0.005 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    MOLM-13 GI50
    0.056 μM
    Compound: 2
    Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    MOLM-13 GI50
    0.056 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay
    Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay
    		[PMID: 23618709]
    MOLM-13 GI50
    0.056 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method
    Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method
    		[PMID: 21708468]
    MOLM-13 IC50
    8.7 nM
    Compound: Sorafenib
    Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    		[PMID: 35033885]
    MOLT-4 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    MOLT-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    MOLT-4 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    MOLT-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    MOLT-4 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method
    Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    MOLT-4 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    MOLT-4 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    MOLT-4 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    MOLT-4 IC50
    5.94 μM
    Compound: Sor
    Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    MOLT-4 GI50
    9 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human MOLT4 after 72 hrs by MTS method
    Antiproliferation activity against human MOLT4 after 72 hrs by MTS method
    		[PMID: 21708468]
    MRC5 IC50
    11.1 μM
    Compound: 1
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 36270111]
    MRC5 IC50
    24.11 μM
    Compound: Sorafenib
    Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    MV4-11 IC50
    < 0.006 μM
    Compound: Sor
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay
    Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay
    		[PMID: 29360358]
    MV4-11 GI50
    0.0009 μM
    Compound: 3
    Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay
    Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay
    		[PMID: 32272419]
    MV4-11 IC50
    0.004 μM
    Compound: Sorafenib
    Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay
    Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay
    		[PMID: 29357250]
    MV4-11 IC50
    0.007 μM
    Compound: Sorafenib
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26342867]
    MV4-11 IC50
    0.007 μM
    Compound: Sorafenib
    Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    		[PMID: 23362959]
    MV4-11 IC50
    0.015 μM
    Compound: 2
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    MV4-11 GI50
    0.03 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method
    Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method
    		[PMID: 21708468]
    MV4-11 GI50
    0.043 μM
    Compound: 2
    Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    MV4-11 GI50
    0.043 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay
    Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay
    		[PMID: 23618709]
    MV4-11 IC50
    0.3 μM
    Compound: Sorafenib
    Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    MV4-11 IC50
    0.3 μM
    Compound: Sorafenib
    Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    MV4-11 IC50
    0.51 μM
    Compound: 1
    Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay
    		[PMID: 31053508]
    MV4-11 IC50
    0.87 nM
    Compound: 4
    Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay
    Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay
    		10.1039/C1MD00175B
    MV4-11 IC50
    0.87 nM
    Compound: BAY-439006, Sorafenib
    Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay
    		[PMID: 19754199]
    MV4-11 IC50
    0.87 nM
    Compound: Sorafenib
    Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay
    Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay
    		[PMID: 19654408]
    MV4-11 IC50
    1.59 nM
    Compound: Sorafenib
    Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
    Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 31103903]
    MV4-11 IC50
    7.7 nM
    Compound: Sorafenib
    Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
    		[PMID: 35033885]
    MX1 IC50
    8.27 μM
    Compound: Sorafenib
    Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay
    Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay
    		[PMID: 24675135]
    NCI/ADR-RES IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method
    Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI/ADR-RES IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI/ADR-RES GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H1417 IC50
    5.84 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H146 IC50
    8.01 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H1650 IC50
    18.09 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H1975 EC50
    > 1000 nM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
    		[PMID: 27010810]
    NCI-H1975 IC50
    9.27 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H211 IC50
    16.47 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H2170 IC50
    22.59 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H226 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H226 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H226 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H226 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H226 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H226 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H226 IC50
    7.92 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H23 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H23 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H23 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H23 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H23 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H23 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H322M IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H322M GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H322M IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    NCI-H322M GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H322M IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H322M GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H322M GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H460 IC50
    10.8 μM
    Compound: Sorafenib
    Cytotoxicity against human H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human H460 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    NCI-H460 IC50
    2.15 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32739648]
    NCI-H460 IC50
    2.19 μM
    Compound: Sorafenib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    NCI-H460 IC50
    2.19 μM
    Compound: 5
    Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25440879]
    NCI-H460 IC50
    2.19 μM
    Compound: 5
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 25086238]
    NCI-H460 IC50
    2.25 μM
    Compound: Sorafenib
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    NCI-H460 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H460 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H460 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H460 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H460 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H460 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H460 IC50
    3.68 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H460 IC50
    3.9 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    NCI-H520 IC50
    11.5 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H522 IC50
    19.26 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 25461318]
    NCI-H522 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    NCI-H522 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    NCI-H522 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method
    Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    NCI-H522 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    NCI-H522 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    NCI-H522 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    NCI-H522 IC50
    5.01 μM
    Compound: Sorafenib
    Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    NCI-H526 IC50
    14.68 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    NCI-H82 IC50
    1.77 μM
    Compound: Sorafenib
    Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
    		[PMID: 34459195]
    Neutrophil IC50
    0.9 μg/mL
    Compound: Sorafenib
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
    		[PMID: 28218000]
    Neutrophil IC50
    1.27 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis
    		[PMID: 23647825]
    Neutrophil IC50
    1.5 μg/mL
    Compound: Sorafenib
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
    		[PMID: 28218000]
    Neutrophil IC50
    1.9 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry
    		[PMID: 25419616]
    Neutrophil IC50
    2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry
    		[PMID: 24388689]
    Neutrophil IC50
    2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis
    		[PMID: 26928286]
    Neutrophil IC50
    3.2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry
    		[PMID: 24388689]
    Neutrophil IC50
    3.2 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis
    		[PMID: 26928286]
    Neutrophil IC50
    5.62 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis
    		[PMID: 23647825]
    Neutrophil IC50
    6.3 μM
    Compound: Sorafenib
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry
    		[PMID: 25419616]
    NIH3T3 GI50
    > 10 μM
    Compound: Sorafenib
    Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
    Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
    		[PMID: 29133048]
    NIH3T3 GI50
    0.32 μM
    Compound: Sorafenib
    Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
    Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
    		[PMID: 29133048]
    NIH3T3 IC50
    24.75 μM
    Compound: Sorafenib, Nexavar
    Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum
    Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum
    		[PMID: 21592628]
    OS-RC-2 IC50
    14 μM
    Compound: Sora
    Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    		[PMID: 31298537]
    OS-RC-2 IC50
    15 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    		[PMID: 29786436]
    OS-RC-2 IC50
    16 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    OS-RC-2 IC50
    7 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay
    		[PMID: 29517908]
    OS-RC-2 IC50
    7 μM
    Compound: Sorafenib
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
    		[PMID: 29297688]
    OVCAR-3 IC50
    12 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    OVCAR-3 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    OVCAR-3 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-3 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-3 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-3 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    OVCAR-3 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    OVCAR-4 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-4 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    OVCAR-4 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-4 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-4 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    OVCAR-4 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-5 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    OVCAR-5 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-5 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-5 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-5 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    OVCAR-5 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-8 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method
    Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    OVCAR-8 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    OVCAR-8 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    OVCAR-8 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    OVCAR-8 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    OVCAR-8 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    PANC-1 IC50
    11.5 μM
    Compound: Sorafenib
    Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 27503679]
    PANC-1 IC50
    12.3 μM
    Compound: Sorafenib
    Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
    Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    PANC-1 IC50
    20 μM
    Compound: Sorafenib
    Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30826508]
    PANC-1 IC50
    9.32 μM
    Compound: Sorafenib
    Growth inhibition of human PANC1 cells after 48 hrs by MTT assay
    Growth inhibition of human PANC1 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    PC-3 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    PC-3 IC50
    10.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells by MTT assay
    Antiproliferative activity against human PC3 cells by MTT assay
    		10.1039/C4MD00536H
    PC-3 IC50
    11.53 μM
    Compound: SOR
    Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    PC-3 IC50
    15.5 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    PC-3 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    PC-3 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    PC-3 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human PC3 cells after 48 hrs by SRB method
    Cytotoxicity against human PC3 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    PC-3 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    PC-3 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    PC-3 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    PC-3 IC50
    24.2 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 24440479]
    PC-3 IC50
    24.2 μM
    Compound: Sorafenib, BAY 43-9006
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 23644219]
    PC-3 IC50
    3.03 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 28340913]
    PC-3 IC50
    3.18 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 28927801]
    PC-3 IC50
    3.24 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 27777009]
    PC-3 IC50
    4.13 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    PC-3 IC50
    6.3 μM
    Compound: 1
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34634618]
    PC-3 IC50
    6.8 μM
    Compound: Sorafenib, Nexavar, BAY-439006
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 23021967]
    PC-3 IC50
    8.08 μM
    Compound: Sorafenib
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27043268]
    PC-3 IC50
    9.77 μM
    Compound: Sorafenib
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
    		[PMID: 32422489]
    PLC-PRF-5 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    PLC-PRF-5 IC50
    29.9 μM
    Compound: Sorafenib
    Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
    		[PMID: 28109948]
    PLC-PRF-5 IC50
    7.51 μM
    Compound: Sor
    Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    Raji IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    Raji IC50
    3.94 μM
    Compound: Sor
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    Ramos IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    Rhabdomyosarcoma cell CC50
    7.05 μM
    Compound: Sorafenib
    Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay
    Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay
    		[PMID: 27288186]
    RKO IC50
    24.18 μM
    Compound: Sorafenib
    Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    RPMI-8226 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    RPMI-8226 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    RPMI-8226 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    RPMI-8226 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    RPMI-8226 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    RS4-11 IC50
    > 5 μM
    Compound: 2
    Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay
    Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    RS4-11 IC50
    2 nM
    Compound: Sorafenib
    Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    		[PMID: 19654408]
    RS4-11 IC50
    3.2 nM
    Compound: Sorafenib
    Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
    		[PMID: 19654408]
    RS4-11 GI50
    9.3 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay
    		[PMID: 23618709]
    RS4-11 GI50
    9.4 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method
    Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method
    		[PMID: 21708468]
    RXF 393 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    RXF 393 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    RXF 393 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    RXF 393 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    RXF 393 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SF-268 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SF-268 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SF-268 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SF268 cells after 48 hrs by SRB method
    Cytotoxicity against human SF268 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SF-268 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SF-268 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SF-268 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SF-295 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SF-295 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SF-295 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SF295 cells after 48 hrs by SRB method
    Cytotoxicity against human SF295 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SF-295 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SF-295 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SF-295 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SF-539 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SF-539 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SF-539 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SF539 cells after 48 hrs by SRB method
    Cytotoxicity against human SF539 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SF-539 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SF-539 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SF-539 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    Sf9 IC50
    < 100 nM
    Compound: Sorafenib
    Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay
    Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay
    		[PMID: 23442188]
    Sf9 IC50
    < 100 nM
    Compound: Sorafenib
    Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay
    Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay
    		[PMID: 23442188]
    Sf9 IC50
    0.003 μM
    Compound: BAY-439006, 3
    Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    0.018 μM
    Compound: BAY-439006, 3
    Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    0.02 μM
    Compound: 2, BAY-43-9006
    Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis
    Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis
    		[PMID: 23618709]
    Sf9 IC50
    0.042 μM
    Compound: 2
    Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay
    		[PMID: 26081023]
    Sf9 IC50
    0.044 μM
    Compound: 2
    Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay
    Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay
    		[PMID: 26081023]
    Sf9 IC50
    0.054 μM
    Compound: 2, BAY-43-9006
    Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis
    Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis
    		[PMID: 23618709]
    Sf9 IC50
    0.054 μM
    Compound: BAY-439006, 3
    Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay
    Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    0.057 μM
    Compound: Sorafenib
    Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay
    Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay
    		[PMID: 30826508]
    Sf9 IC50
    0.1 μM
    Compound: I; BAY 43-9006
    Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay
    Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay
    		[PMID: 31284081]
    Sf9 IC50
    14520 nM
    Compound: 59
    Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay
    Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay
    		[PMID: 31622096]
    Sf9 IC50
    3.8 μM
    Compound: 2
    Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay
    		[PMID: 26081023]
    Sf9 IC50
    3.8 μM
    Compound: 2, BAY-43-9006
    Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis
    Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis
    		[PMID: 23618709]
    Sf9 IC50
    3.8 μM
    Compound: BAY-439006, 3
    Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay
    Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay
    		[PMID: 21708468]
    Sf9 IC50
    90 nM
    Compound: sorafenib
    Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay
    Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay
    		[PMID: 23562241]
    SGC-7901 IC50
    10.37 μM
    Compound: Sorafenib
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    SGC-7901 IC50
    101 μM
    Compound: Sorafenib
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    SGC-7901 IC50
    102 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SGC-7901 IC50
    11.5 μM
    Compound: Sorafenib
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    SGC-7901 IC50
    6.9 μM
    Compound: Sorafenib
    Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
    		[PMID: 23454017]
    SGC-7901 IC50
    8.84 μM
    Compound: Sorafenib
    Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    SH-SY5Y IC50
    > 100 μM
    Compound: Sorafenib
    Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay
    		[PMID: 31488358]
    SH-SY5Y IC50
    19.54 μM
    Compound: Sorafenib
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    		[PMID: 23871909]
    SH-SY5Y IC50
    27.71 μM
    Compound: Sorafenib
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    		[PMID: 27162123]
    SH-SY5Y IC50
    5.73 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SH-SY5Y IC50
    5.73 μM
    Compound: Sorafenib
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
    		[PMID: 24315192]
    SK-BR-3 IC50
    5.21 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SK-HEP1 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SK-HEP1 IC50
    1.98 μM
    Compound: sorafenib
    Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    SK-HEP1 IC50
    7.3 μM
    Compound: 1
    Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34634618]
    SK-HEP1 IC50
    8.37 μM
    Compound: Sor
    Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SK-HEP1 IC50
    9.64 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 32791397]
    SK-MEL IC50
    10 μM
    Compound: Sorafenib
    Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 33882233]
    SK-MEL-2 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-MEL-2 IC50
    11.35 μM
    Compound: Sorafenib
    Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay
    Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay
    		[PMID: 28242553]
    SK-MEL-2 IC50
    11.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay
    Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 30529543]
    SK-MEL-2 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-MEL-2 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-MEL-2 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-MEL-2 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-MEL-2 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-MEL-28 EC50
    1.3 μM
    Compound: 1, sorafenib, BAY-439006
    Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay
    Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay
    		[PMID: 18942827]
    SK-MEL-28 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    SK-MEL-28 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method
    Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-MEL-28 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-MEL-28 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-MEL-28 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-MEL-28 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-MEL-28 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-MEL-28 IC50
    9.45 μM
    Compound: Sorafenib
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 30955995]
    SK-MEL-30 IC50
    3900 nM
    Compound: 1
    Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay
    Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 29461827]
    SK-MEL-5 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-MEL-5 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-MEL-5 GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method
    Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-MEL-5 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-MEL-5 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-MEL-5 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-MEL-5 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    SK-OV-3 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SK-OV-3 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SK-OV-3 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SK-OV-3 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SK-OV-3 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SK-OV-3 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SK-OV-3 IC50
    9.25 μM
    Compound: Sorafenib
    Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    SMMC-7721 IC50
    > 10 μM
    Compound: Sorafenib
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32842729]
    SMMC-7721 IC50
    0.37 μM
    Compound: Sorafenib
    Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 25982075]
    SMMC-7721 IC50
    0.65 μM
    Compound: BAY-43-9006
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
    		[PMID: 26342134]
    SMMC-7721 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26753815]
    SMMC-7721 IC50
    10.61 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 29032031]
    SMMC-7721 IC50
    17.3 μM
    Compound: sorafenib
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA
    		[PMID: 21504204]
    SMMC-7721 IC50
    18.7 μM
    Compound: Sorafenib
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 24300920]
    SMMC-7721 IC50
    2.37 μM
    Compound: sorafenib
    Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay
    		[PMID: 35639640]
    SMMC-7721 IC50
    4.88 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    SMMC-7721 IC50
    6.23 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    		[PMID: 22721924]
    SMMC-7721 IC50
    8.8 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36745506]
    SMMC-7721 IC50
    9.86 μM
    Compound: BAY-93-4006
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    		10.1039/C3MD00192J
    SMMC-7721 IC50
    9.96 μM
    Compound: Sorafenib
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    		[PMID: 25637123]
    SN12C IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SN12C GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SN12C GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SN12C cells after 48 hrs by SRB method
    Cytotoxicity against human SN12C cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SN12C IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SN12C GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SN12C GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SNB-19 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SNB-19 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SNB-19 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human SNB19 cells after 48 hrs by SRB method
    Cytotoxicity against human SNB19 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SNB-19 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SNB-19 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SNB-19 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SNB-75 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SNB-75 IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    SNB-75 GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human SNB75 cells after 48 hrs by SRB method
    Cytotoxicity against human SNB75 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SNB-75 IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SNB-75 GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SNU-387 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SNU-387 IC50
    12.33 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35525080]
    SNU-387 IC50
    258.91 μM
    Compound: Sorafenib
    Antiproliferative activity against human SNU-387 cells by MTT assay
    Antiproliferative activity against human SNU-387 cells by MTT assay
    		[PMID: 34128674]
    SNU-387 IC50
    8.29 μM
    Compound: Sor
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SNU-398 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SNU-398 IC50
    3.38 μM
    Compound: Sor
    Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SR IC50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SR GI50
    3.16 μM
    Compound: 1
    Cytotoxicity against human SR cells after 48 hrs by SRB method
    Cytotoxicity against human SR cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SR IC50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SR GI50
    3.16 μM
    Compound: Sorafenib
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SR GI50
    3.16 μM
    Compound: Sorafenib
    Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    SU-DHL-6 IC50
    0.001 μM
    Compound: Sorafenib
    Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    SU-DHL-6 IC50
    3.82 μM
    Compound: Sor
    Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
    		[PMID: 29360358]
    SW480 GI50
    14.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36126227]
    SW480 GI50
    15.6 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 36068975]
    SW-620 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    SW-620 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    SW-620 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human SW620 cells after 48 hrs by SRB method
    Cytotoxicity against human SW620 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    SW-620 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    SW-620 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    SW-620 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    T-24 IC50
    5.31 μM
    Compound: Cpd S
    Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
    Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
    		[PMID: 32827851]
    T47D IC50
    0.61 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
    		[PMID: 25778995]
    T47D IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    T47D GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    T47D GI50
    1.58 μM
    Compound: 1
    Cytotoxicity against human T47D cells after 48 hrs by SRB method
    Cytotoxicity against human T47D cells after 48 hrs by SRB method
    		[PMID: 26590508]
    T47D IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    T47D GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    T47D GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    T47D IC50
    1.6 μM
    Compound: I; BAY 43-9006
    Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay
    		[PMID: 31284081]
    T47D IC50
    6.4 μM
    Compound: Sorafenib
    Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
    		[PMID: 33328104]
    THP-1 IC50
    0.31 μM
    Compound: 2
    Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    TK-10 IC50
    3.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    TK-10 GI50
    3.98 μM
    Compound: Sorafenib
    Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    TK-10 IC50
    3.98 μM
    Compound: Sorafenib
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    TK-10 GI50
    3.98 μM
    Compound: Sorafenib
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    TK-10 GI50
    3.98 μM
    Compound: Sorafenib
    Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    TT IC50
    1.4 nM
    Compound: sorafenib
    Antiproliferative activity against human TT cells after 13 days by fluorescence assay
    Antiproliferative activity against human TT cells after 13 days by fluorescence assay
    		[PMID: 18849971]
    U-251 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    U-251 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    U-251 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    U-251 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human U251 cells after 48 hrs by SRB method
    Cytotoxicity against human U251 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    U-251 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    U-251 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    U-251 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    U-251 IC50
    24.71 μM
    Compound: Sorafenib
    Cytotoxicity against human U251 cells after 48 hrs by MTT assay
    Cytotoxicity against human U251 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    U-87MG ATCC IC50
    12.67 μM
    Compound: Sorafenib
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36508995]
    U-87MG ATCC IC50
    15.57 μM
    Compound: Sorafenib
    Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
    Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    U-87MG ATCC IC50
    21.07 μM
    Compound: Sorafenib
    Cytotoxicity against human U87 cells after 48 hrs by MTT assay
    Cytotoxicity against human U87 cells after 48 hrs by MTT assay
    		[PMID: 20435479]
    U-87MG ATCC IC50
    8.46 μM
    Compound: Sorafenib
    Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
    		[PMID: 35462164]
    U-937 IC50
    > 3 μM
    Compound: Sorafenib
    Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
    		[PMID: 24641103]
    U-937 IC50
    > 5 μM
    Compound: 2
    Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
    Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
    		[PMID: 20570526]
    U-937 GI50
    2.34 μM
    Compound: Sorafenib
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    		[PMID: 29459144]
    U-937 GI50
    2.74 μM
    Compound: Sorafenib
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
    		[PMID: 26318067]
    U-937 GI50
    2.74 μM
    Compound: Sorafenib
    Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 24878193]
    U-937 GI50
    2.85 μM
    Compound: Sorafenib
    Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay
    Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay
    		[PMID: 22014755]
    U-937 GI50
    3.4 μM
    Compound: 2
    Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay
    		[PMID: 26081023]
    U-937 GI50
    3.4 μM
    Compound: 2, BAY-43-9006
    Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay
    Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay
    		[PMID: 23618709]
    U-937 GI50
    3.4 μM
    Compound: BAY-439006, 3
    Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method
    Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method
    		[PMID: 21708468]
    UACC-257 IC50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    UACC-257 GI50
    2 μM
    Compound: Sorafenib
    Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    UACC-257 GI50
    2 μM
    Compound: 1
    Cytotoxicity against human UACC257 cells after 48 hrs by SRB method
    Cytotoxicity against human UACC257 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    UACC-257 IC50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    UACC-257 GI50
    2 μM
    Compound: Sorafenib
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    UACC-257 GI50
    2 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    UACC-62 IC50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    UACC-62 GI50
    1.58 μM
    Compound: Sorafenib
    Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    UACC-62 IC50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    UACC-62 GI50
    1.58 μM
    Compound: Sorafenib
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    UACC-62 GI50
    1.58 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    UACC-62 IC50
    1.95 μM
    Compound: Sorafenib
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay
    		[PMID: 33316752]
    UO-31 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay
    Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay
    		[PMID: 35764033]
    UO-31 GI50
    2.51 μM
    Compound: Sorafenib
    Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    UO-31 IC50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 34237622]
    UO-31 GI50
    2.51 μM
    Compound: 1
    Cytotoxicity against human UO31 cells after 48 hrs by SRB method
    Cytotoxicity against human UO31 cells after 48 hrs by SRB method
    		[PMID: 26590508]
    UO-31 IC50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 30006168]
    UO-31 GI50
    2.51 μM
    Compound: Sorafenib
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
    		[PMID: 28088086]
    UO-31 GI50
    2.51 μM
    Compound: Sorafenib
    Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 27017549]
    WI-38 GI50
    > 20 μM
    Compound: Sorafenib
    Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
    		[PMID: 35551038]
    WI-38 IC50
    > 30 μM
    Compound: Sorafenib
    Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 33310290]
    WI-38 IC50
    10.65 μM
    Compound: SOR
    Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
    Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
    		[PMID: 35964425]
    WI-38 IC50
    14.7 μM
    Compound: Sorafenib
    Antiproliferative activity against human WI-38 cells measured by MTT assay
    Antiproliferative activity against human WI-38 cells measured by MTT assay
    		[PMID: 35764033]
    WI-38 IC50
    7.54 μM
    Compound: Sorafenib
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    		[PMID: 24826815]
    WI-38 IC50
    8.42 μM
    Compound: Sorafenib
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
    		[PMID: 26991938]
    WM 266-4 IC50
    0.06 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay
    Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay
    		[PMID: 25496804]
    WM 266-4 GI50
    4.5 μM
    Compound: Sorafenib
    Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay
    Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay
    		[PMID: 20199087]
    WM 266-4 GI50
    4.933 μM
    Compound: 2
    Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay
    Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay
    		[PMID: 20148563]
    WM 266-4 IC50
    5 μM
    Compound: Sorafenib
    Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay
    Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay
    		[PMID: 19323560]
    WM 266-4 GI50
    8.1 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay
    Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay
    		[PMID: 23025996]
    WM 266-4 GI50
    8.12 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay
    Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay
    		[PMID: 22583669]
    WM 266-4 GI50
    8.3 μM
    Compound: Sorafenib
    Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay
    Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay
    		[PMID: 22361686]
    WM164 IC50
    4.9 μM
    Compound: sorafenib, velcade
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    		[PMID: 17561392]
    WM164 IC50
    5 μM
    Compound: Sorafenib
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
    		[PMID: 20056548]
    ZR-75-30 IC50
    2.96 μM
    Compound: Sorafenib
    Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay
    Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay
    		[PMID: 29102175]
    体外研究
    (In Vitro)

    Sorafenib (BAY 43-9006) 在生化分析中，还抑制 BRAFwt (IC50=22 nM)，BRAFV599E (IC50=38 nM)，VEGFR-2 (IC50=90 nM)，VEGFR-3 (IC50=20 nM)，PDGFR-β (IC=20 nM) >50=57 nM)、c-KIT (IC50=68 nM) 和 Flt3 (IC50=58 nM)。在 MDA-MB-231 乳腺癌细胞中，Sorafenib 完全阻断 MAPK 通路的激活。细胞与 Sorafenib (0.01 至 3 μM) 预孵育，并以剂量依赖性方式抑制基础 MEK 1/2 和 ERK 1/2 磷酸化 (IC50，分别为 40 和 100 nM)[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Sorafenib 相关抗体:
    体内研究
    (In Vivo)

    Sorafenib 在一组人类肿瘤异种移植模型中表现出广泛的口服抗肿瘤功效。Sorafenib 以 7.5 至 60 mg/kg 的剂量口服给药。与相应的对照组相比，任何处理组都没有致死率，体重减轻也没有增加。在六种模型中的五种模型中，每日口服 Sorafenib (30 至 60 mg/kg) 可在处理期间产生完全的肿瘤停滞[1]。二乙基亚硝胺 (DENA) 组的存活率为 73.3%，Sorafenib 组为 83.3%，而正常对照组为 100%。与正常对照组相比，DENA 组肝脏指数显著增加 (增加 1.51 倍，p<0.05)，而与 DENA 组相比，Sorafenib 处理显示肝脏指数显著降低 (p<0.05)。Sorafenib 组肝脏指数显著降低至低于正常对照组[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    464.83

    Formula

    C21H16ClF3N4O3
    CAS 号
    性状

    固体

    颜色

    White to off-white

    中文名称

    索拉非尼；索拉菲尼
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : ≥ 45 mg/mL (96.81 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    * "≥" means soluble, but saturation unknown.

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.1513 mL 10.7566 mL 21.5132 mL
    5 mM 0.4303 mL 2.1513 mL 4.3026 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 2% DMSO    40% PEG300    5% Tween-80    53% Saline

      Solubility: 4 mg/mL (8.61 mM); 悬浊液; 超声助溶

    • 方案 二

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.08 mg/mL (4.47 mM); 悬浊液; 超声助溶

      此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。

      以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

      生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    请输入您的动物体内配方组成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
    您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
    连续给药周期超过半月以上，请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.92%

    COA (189 KB) HNMR (242 KB) LCMS (120 KB) 元素分析报告 (205 KB)

    产品使用指南 (1538 KB)
    参考文献
    Kinase Assay
    [1]

    To test compound inhibition against various RAF kinase isoforms, Sorafenib is added to a mixture of Raf-1 (80 ng), wt BRAF, or V599E BRAF (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The RAF kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ-[33P]ATP (400 Ci/mol) and incubated at 32°C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Cell Assay
    [1]

    The MDA-MB-231 human mammary adenocarcinoma cell lines are plated at 2×105 cells per well in 12-well tissue culture plates in DMEM growth media (10% heat-inactivated FCS) overnight. Cells are washed once with serum-free media and incubated in DMEM supplemented with 0.1% fatty acid-free BSA containing various concentrations of BAY 43-9006 (0.01, 0.03 , 0.1, 0.3, 1, 3 μM) in 0.1% DMSO for 120 minutes to measure changes in basal pMEK 1/2, pERK 1/2, or pPKB. Cells are washed with cold PBS (PBS containing 0.1 mM vanadate) and lysed in a 1% (v/v) Triton X-100 solution containing protease inhibitors. Lysates are clarified by centrifugation, subjected to SDS-PAGE, transferred to nitrocellulose membranes, blocked in TBS-BSA, and probed with anti-pMEK 1/2 (Ser217/Ser221; 1:1000), anti-MEK 1/2, anti-pERK 1/2 (Thr202/Tyr204; 1:1000), anti-ERK 1/2, anti-pPKB (Ser473; 1:1000), or anti-PKB primary antibodies. Blots are developed with horseradish peroxidase (HRP)-conjugated secondary antibodies and developed with Amersham ECL reagent on Amersham Hyperfilm[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1][2]

    Mice[1]
    Female NCr-nu/nu mice are used. Mice bearing 75 to 150 mg tumors are treated orally with Sorafenib (7.5 to 60 mg/kg), administered daily for 9 days. In each model, Sorafenib produces dose-dependent tumor growth inhibition with no evidence of toxicity, as measured by increased weight loss relative to control animals or drug-related lethality. In parallel to the antitumor efficacy studies, additional groups of four mice bearing 100 to 200 mg tumors are treated orally with vehicle or Sorafenib (30 to 60 mg/kg), administered daily for 5 days, which is the shortest treatment duration producing complete tumor stasis in the treated groups.
    Rats[2]
    In the study, 100- to 120-g male albino rats are utilized. After acclimatization period, rats are weighed and randomly divided into three groups: Group 1 (normal control group; n=10) is given the vehicle daily for 8 weeks. Group 2 (DENA group; n=15) receive i.p. single dose of 200 mg/kg DENA. Group 3 (Sorafenib group; n=12) is given Sorafenib orally at a dose of 10 mg/kg daily for 2 weeks, 6 weeks after DENA i.p. injection. At the end of the experiment (8 weeks), rats are weighed, anesthetized by ether, and killed, and their livers are dissected. Fresh liver is washed twice with ice-cold saline, dried on clean paper towel, and weighed. Liver index is calculated as liver weight (g)/final body weight (g)×100. The liver is divided into five portions: one portion is preserved in 10 % formalin for histopathological examination and the other portions are immediately frozen in liquid nitrogen and stored at −80°C.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    Sorafenib 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1513 mL 10.7566 mL 21.5132 mL 53.7831 mL
    5 mM 0.4303 mL 2.1513 mL 4.3026 mL 10.7566 mL
    10 mM 0.2151 mL 1.0757 mL 2.1513 mL 5.3783 mL
    15 mM 0.1434 mL 0.7171 mL 1.4342 mL 3.5855 mL
    20 mM 0.1076 mL 0.5378 mL 1.0757 mL 2.6892 mL
    25 mM 0.0861 mL 0.4303 mL 0.8605 mL 2.1513 mL
    30 mM 0.0717 mL 0.3586 mL 0.7171 mL 1.7928 mL
    40 mM 0.0538 mL 0.2689 mL 0.5378 mL 1.3446 mL
    50 mM 0.0430 mL 0.2151 mL 0.4303 mL 1.0757 mL
    60 mM 0.0359 mL 0.1793 mL 0.3586 mL 0.8964 mL
    80 mM 0.0269 mL 0.1345 mL 0.2689 mL 0.6723 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Sorafenib284461-73-0Bay 43-9006索拉非尼索拉菲尼RafVEGFRFLT3AutophagyApoptosisFerroptosisRaf kinasesVascular endothelial growth factor receptorCluster of differentiation antigen 135CD135Fms like tyrosine kinase 3Inhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Sorafenib
    目录号：
    HY-10201
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z